Importance of bile acid structure in amelioration of griseofulvin-induced murine protoporphyric hepatopathy.
This study investigated the effects of bile acid structure on griseofulvin-induced murine hepatopathy and explored the mechanism(s) of cholestasis in this model of protoporphyria. Mice were fed pulverized chow with cholate, chenodeoxycholate, or ursodeoxycholate, with or without griseofulvin. After 1 to 4 weeks, bile flow, bile acid excretion and composition, biliary protoporphyrin excretion, hepatic protoporphyrin contents, liver histology, and griseofulvin plasma concentrations were determined. Additionally, bile acid absorption was measured. Griseofulvin induced a progressive increase in liver weight, hepatic protoporphyrin content, and histopathologic evidence of cholestasis. Biliary protoporphyrin excretion increased and pigmented gallbladder microliths developed. Bile flow and bile acid excretion fell in relation to liver weight but not in relation to body weight. Cholic acid augmented biliary protoporphyrin excretion, markedly reduced hepatic protoporphyrin content, and obviated the development of intrahepatic biliary thrombi. Ursodeoxycholate and chenodeoxycholate both reduced biliary protoporphyrin excretion. This was associated with bile acid compositional changes, particularly a fall in cholic acid. Although histopathologic abnormalities were not altered, these bile acids reduced hepatic protoporphyrin contents. Bile acid treatments with griseofulvin all increased bile flow and bile acid excretion relative to controls, but differences in the relationship of bile flow to bile acid structure on protoporphyrin disposition. They document biliary excretion as the principal mode of cholic acid amelioration of griseofulvin-induced hepatopathy. They also suggest distinctive roles for griseofulvin and protoporphyrin in the generation of the cholestasis.
Berenson
M M
MM
Internal Medicine Service, Veterans Affairs Medical Center, Salt Lake City, Utah.
Welch
V
V
Garcia-Marin
J J
JJ
D000042:Absorption; D000818:Animals; D001646:Bile / Q000187:drug effects / Q000378:metabolism; D001647:Bile Acids and Salts / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology*; D056486:Chemical and Drug Induced Liver Injury; D002635:Chenodeoxycholic Acid / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced; D019826:Cholic Acid; D002793:Cholic Acids / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology; D005260:Female; D006118:Griseofulvin / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008107:Liver Diseases / Q000378:metabolism / Q000473:pathology; D051379:Mice; D011524:Protoporphyrins / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014580:Ursodeoxycholic Acid / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology
D001647:Bile Acids and Salts; D002793:Cholic Acids; D011524:Protoporphyrins; D002635:Chenodeoxycholic Acid; D006118:Griseofulvin; D014580:Ursodeoxycholic Acid; D019826:Cholic Acid